Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution

Pharmacogenetics

Volumn 7, Issue 3, 1997, Pages 193-202

  Marez, D ^a   Legrand, M ^a   Sabbagh, N ^a   Lo Guidice, J M ^a   Spire, C ^a   Lafitte, J J ^a   Meyer, U A ^b   Broly, F ^a  

^a UNIV LILLE   (France)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

CYP2D6 polymorphism; Pharmacogenetics; Population; SSCP

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEBRISOQUINE; DEXTROMETHORPHAN; SPARTEINE;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG METABOLISM; EUROPE; HUMAN; HUMAN EXPERIMENT; MAJOR CLINICAL STUDY; MUTATION; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

ALLELES; CYTOCHROME P-450 CYP2D6; EUROPE; GENE AMPLIFICATION; GENE FREQUENCY; GENOTYPE; HUMANS; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA;

EID: 0030860004     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199706000-00004     Document Type: Article

References (52)

1. Aǵndez JAG, Ledesma MC, Ladero JM, Benitez J. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 1995: 57, 265-269.
2. Alvan G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990: 39, 533-537.
3. Armstrong M, Fairbrother K, Idle JR, Daly AK. The cytochrome P450 CYP2D6 allelic variant CYP2D6J and related polymorphisms in a European population. Pharmacogenetics 1994: 4, 73-81.
4. Bertilsson L. Geographic/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995: 29, 192-209.
5. Beyeler C, Armstrong M, Bird HA, Idle JR, Daly AK. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility for ankylosing spondylitis and rheumatoid arthritis. Ann Rheum Dis 1996: 55, 66-68.
6. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 1991: 8, 545-558.
7. Broly F, Meyer UA. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene. Pharmacogenetics 1993: 3, 923-926.
8. Broly, F, Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995a: 5, 373-384.
9. Broly F, Marez D, Lo-Guidice JM, Sabbagh N, Legrand M, Boone P, Meyer UA. A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. Hum Genet 1995b: 96, 601-603.
10. Brosen K, Nielsen PN, Brusgaard K, Gram LF, Skjodt K. CYP2D6 genotype determination in the Danish population. Eur J Clin Pharmacol 1994: 47, 221-225.
11. Crespi CL, Penman BW, Gelboin HV, Gonzalez FJ. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis 1991: 12, 1197-1201.
12. Dahl ML, Johannson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 1992: 51, 12-17.
13. Dahl ML, Johannson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 1995a: 274, 516-520.
14. Dahl ML, Yue QY, Roh HK, Johansson I, Säwe J, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995b: 5, 159-164.
15. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994: 102, 55-61.
16. Daly AK. Molecular basis of polymorphic drug metabolism. J Mol Med 1995: 73, 539-553.
17. Daly AK, Leathart JBS, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet 1995: 95, 337-341.
18. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
19. Ellis SW, Hayhurst GT, Smith G, Lightfoot T, Wong MMS, Simula AP, Ackland MJ, Sternberg MJE, Lennard MS, Tucker GT, Wolf CR. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6. J Biol Chem 1995: 270, 29055-29058.
20. Evans WE, Relling MV. Xbal 16- plus 9-kilobase DNA restriction fragments identify a mutant allele for debrisoquin hydroxylase: report of a family study. Mol Pharmacol 1990: 37, 639-642.
21. Evert B, Griese EU, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schiedeberg' Arch Pharmacol 1994a: 350, 434-439.
22. Evert B, Griese EU, Eichelbaum M. Cloning and sequencing of a new non-functional CYP2D6 allele: Deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994b: 4, 271-274.
23. Fonne-Pfister R, Bargetzi MJ, Meyer UA. MPTP, the neurotoxin inducing Parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P56buf1, P450db1) catalysing debrisoquine 4-hydroxylation. Biochem Biophys Res Comm 1987: 148, 1144-1150.
24. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
25. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotides sequences. J Biol Chem 1992: 267, 83-90.
26. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 1990: 336, 529-532.
27. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D6 locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
28. Johansson I, Oscarson M, Yeu QY, Bertilsson L, Sjöqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P450D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994: 46, 452-459.
29. Johansson I, Lundqvist E, Dahl ML, Ingelman-Sundberg M. PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 1996: 6, 351-355.
30. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990: 265, 17209-17214.
31. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez F. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene and a pseudogene. Am J Hum Genet 1989: 45, 889-904.
32. Koymans LMH, Vermeulen NPE, Baarslag A, Donné-Op den Kelder GM. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building. J Comput-Aided Mol Design 1993: 7, 281-289.
33. Kroemer HK, Eichelbaum M. "It's the genes, stupid" Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995: 56, 2285-2298.
34. Llerena A, Edman G, Cobaleda J, Benitez J, Schalling D, Bertilsson L. Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psych Scand 1993: 87, 23-28.
35. Lovlie R, Daly A, Molven A, Idle JR, Steen V. Ultrarapid metabolizers of debrisoquine: characterization and PCR-based detection of alleles with duplication of the CYP2D6 gene. FEBS Lett 1996: 392, 30-34.
36. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995: 5, 305-311.
37. Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Boone P, Broly F. An additional allelic variant of the CYP2D6 gene causing impaired metabolism of sparteine. Hum Genet 1996: 97, 668-670.
38. Masimirembwa CM, Johansson I, Hasler JA, Ingelman-Sundberg M. Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population. Pharmacogenetics 1993: 3, 275-280.
39. Matsunaga E, Zeugin T, Zanger UM, Aoyama T, Meyer UA, Gonzalez FJ. Sequence requirement for Cytochrome P-45IID1 catalytic activity. A single amino acid change specifically decreases Vmax of the enzyme for bufuralol but not debrisoquine hydroxylation. J Biol Chem 1990: 265, 17197-17201.
40. 3H)GBR-12935 binding proteins. Arch Biochem Biophys 1990: 276, 424-432.
41. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994: 3, 923-926.
42. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988: 85, 5240-5243.
43. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995: 5, 215-223.
44. Steiner E, Iselius L, Alvan G, Lindsten J, Sjoqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 1985: 38, 394-401.
45. Suzuki T, Fujita S, Narimatsu S, Masubuchi Y, Tachibana M, Ohta S, Hirobe M. Cytochrome P450 isoenzymes catalyzing 4-hydroxylation of parkinsonism-related compound 1,2,3,4-tetrahydroisoquinoline in rat liver microsomes. FASEB J 1992: 6, 771-776.
46. Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol 1994: 46, 417-424.
47. Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-) cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Mol Pharmacol 1991a: 40, 63-68.
48. Tyndale RF, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin HV, Meyer UA, Gonzalez FJ. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1991b: 1, 26-32.
49. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993: 53, 410-418.
50. Wolf CR, Smith CAD. Metabolic polymorphisms in carcinogen metabolising enzymes and cancer susceptibility. Brit Med Bull 1994: 50, 718-731.
51. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez FJ, Kamataki T. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996: 6, 395-401.
52. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993: 3, 256-263.